Urine mycotoxin tests for mold exposure: detection is not a diagnosis
A urine mycotoxin result does not diagnose illness, identify a building as the source, or establish a disease-causing dose. In a 2015 investigation, CDC reported no FDA-approved human urine test, possible low-level food exposure in healthy people, and no established disease-predictive levels.
A urine mycotoxin test may detect a chemical or metabolite, but the result alone does not diagnose an illness, identify a building as the source, or establish that the measured level caused symptoms. In a 2015 investigation, CDC reported that no FDA-approved test existed for mycotoxins in human urine, low levels could occur in healthy people through food exposure, and disease-predictive urine levels had not been established.1
The decision is easiest to audit when four jobs remain separate: measuring a specimen, evaluating health, investigating a building, and remediating moisture. One commercial report should not silently perform all four.
A positive result answers a narrow analytical question
Detection means the assay produced a signal above its reporting threshold for the specimen that arrived. Interpretation still depends on identity, calibration, detection and quantitation limits, sample timing, stability, contamination controls, metabolism, hydration or urine dilution, and reference data.
| Question | What could support it | What a urine result alone cannot prove |
|---|---|---|
| Was an analyte detected? | A validated analytical method, quality controls, units, uncertainty, and specimen record | That the concentration is clinically harmful |
| Where did exposure occur? | A source investigation that considers food, work, home, hobbies, timing, and environmental conditions | That one named building caused the result |
| Did exposure cause illness? | A clinical evaluation and condition-specific evidence linking a validated exposure measure to the health outcome | A diagnosis from a proprietary reference flag |
| Does a building need action? | Visible moisture, water damage, odor, material condition, ventilation, and qualified inspection | That a urine level measures the building or sets a cleanup threshold |
Ask whether the laboratory reports the parent mycotoxin, a metabolite, or a conjugated form; how results are normalized; and what the comparison range represents. A color-coded “high” value needs a source for the threshold and evidence that crossing it predicts the claimed condition.
Food exposure breaks the building-only inference
CDC’s investigation explains that mycotoxins are metabolites produced by fungi and that low levels can occur in healthy people because these substances may be present in foods.1 That does not show that every detected result came from food. It shows why urine detection cannot identify a building without a validated source-attribution method.
Timing matters too. Urinary excretion can reflect recent intake or metabolism rather than a stable stored burden, depending on the analyte. A seller should not convert one spot specimen into a history of exposure without pharmacokinetic evidence for that exact marker.
“Detox” treatment can further complicate interpretation when the company claims a changing level proves release from tissues. A before-and-after number does not validate that mechanism unless collection, hydration, analytical variation, exposure, and an independent clinical outcome are accounted for.
CLIA certification does not establish clinical validity
CLIA regulates laboratory testing quality and analytical performance. CMS has explained that CLIA does not assess the clinical validity of a laboratory-developed test—the relationship between a result and a disease or clinical condition.4 A CLIA certificate therefore cannot answer whether a urine mycotoxin threshold diagnoses a mold-related illness.
Keep three records separate:
- Analytical validity: does the method detect and measure the analyte reliably in urine?
- Clinical validity: does a defined result accurately identify or predict the claimed condition in the intended population?
- Clinical utility: does using the result to choose an action improve an important outcome compared with a reasonable alternative?
A laboratory can be competent at measurement while a marketer overstates the meaning. Conversely, a useful building remediation decision may not require a biomarker at all.
Biomonitoring is not a personal risk verdict
CDC’s current biomonitoring interpretation guidance says that finding an environmental chemical in blood or urine does not by itself mean the chemical causes disease and does not identify the source or route of exposure.2 Health interpretation requires additional exposure and dose–response research.
That principle protects against two opposite errors. A detectable value should not be used to diagnose a broad set of nonspecific symptoms. An undetected value should not be used to dismiss visible water damage, respiratory symptoms, or another health concern outside the assay’s window and analytes.
If a report assigns a “toxic burden” or “mold colonization” score, ask for:
An association study or case series cannot supply all of these fields.
Building assessment follows moisture, not a urine threshold
NIOSH says there are no health-based standards for mold or other biological agents in indoor air and does not recommend routine air sampling. It emphasizes visual inspection, musty odors, moisture sources, and correcting dampness or water damage.3 Short-term air or surface samples can miss variation and may not translate into health risk.
The practical building record includes the leak or moisture history, humidity and ventilation, visible damage, affected materials, occupant locations and timing, photographs, qualified inspection findings, repair scope, containment when needed, drying and material removal, and post-remediation moisture control.
A laboratory report should not delay fixing an active leak. Nor should a generic “mold-free” certificate replace inspection of the original moisture cause.
Health evaluation and property disputes need different evidence
Symptoms such as cough, wheeze, eye or skin irritation, congestion, headache, or fatigue have many possible causes. A health professional can evaluate symptom pattern, severity, timing, known allergies or asthma, infection, medicines, work and home contexts, and signs needing urgent attention. That clinical task is different from proving a landlord, employer, builder, or insurer is legally responsible.
Treomark does not adjudicate a diagnosis or property claim. For a disputed exposure, preserve original reports, specimen chain of custody, photographs, dates, repair communications, clinician records, and laboratory method information. Avoid destructive remediation or sampling performed solely to create evidence without qualified guidance.
Urgent breathing difficulty, severe allergic symptoms, confusion, fainting, or rapidly worsening illness needs an appropriate care route independent of a commercial test result.
Do not let a package create a closed loop
Some programs sell the initial urine panel, interpretive visit, branded supplements or binders, repeated testing, and a “clearance” endpoint defined by the same proprietary range. Financial integration does not prove the program is wrong, but it creates a reason to demand independent validity and stop rules.
Ask what happens if symptoms improve while the score stays high, if the score falls while symptoms persist, or if a second laboratory disagrees. The plan should not define every discordant result as a reason to buy another cycle.
Separate the four workstreams
- Freeze the test claim. Write the exact analyte, method, units, threshold, specimen timing, and condition the seller says the result identifies.
- Audit analytical validity. Request quality controls, detection and quantitation limits, calibration, precision, interferences, normalization, and proficiency evidence.
- Demand clinical validity. Find independent validation against an accepted condition standard in the intended population, with predictive performance and uncertainty.
- Investigate the environment directly. Document moisture, water damage, materials, ventilation, timing, and qualified inspection rather than using urine as a building meter.
- Evaluate health on its own track. Use symptoms, history, examination, and established testing as appropriate without making the commercial panel the diagnosis.
- Predefine action and stopping. Ask what finding changes remediation or clinical care, what outcome matters, and when repeat testing or products end.
The decisive question is: “What validated clinical conclusion does this exact urine level support beyond analytical detection, and what independent evidence connects it to my claimed source, symptoms, and proposed action?”
Sources
- Centers for Disease Control and Prevention. Use of unvalidated urine mycotoxin tests for the clinical diagnosis of illness — United States, 2014. CDC investigation and guidance on FDA approval, food exposure, lack of disease-predictive levels, CLIA limits, and recommendations against biologic testing of occupants of water-damaged buildings. Accessed .
- Centers for Disease Control and Prevention. Interpretation of biomonitoring data. Current CDC framework explaining that detection in blood or urine does not alone establish health effects, source, or disease risk. Accessed .
- National Institute for Occupational Safety and Health. Mold, testing, and remediation. Current building guidance on health-based indoor standards, routine sampling limits, visual and moisture assessment, and remediation priorities. Accessed .
- Centers for Medicare & Medicaid Services. Frequently asked questions: laboratory-developed tests and CLIA. Narrow explanation that CLIA addresses laboratory analytical performance and does not establish a test's clinical validity. Accessed .